Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have earned a consensus recommendation of “Buy” from the twenty-one analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $124.50.
Several brokerages have weighed in on ALNY. Stifel Nicolaus lifted their price objective on Alnylam Pharmaceuticals from $110.00 to $116.00 and gave the company a “buy” rating in a report on Monday, April 15th. BMO Capital Markets lifted their price objective on Alnylam Pharmaceuticals from $126.00 to $128.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Cowen dropped their price objective on Alnylam Pharmaceuticals from $147.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday. BidaskClub raised Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 11th. Finally, Cantor Fitzgerald boosted their price target on Alnylam Pharmaceuticals from $135.00 to $138.00 and gave the stock an “overweight” rating in a report on Monday, April 15th.
NASDAQ ALNY traded down $2.19 during midday trading on Friday, hitting $80.78. The company had a trading volume of 711,761 shares, compared to its average volume of 760,153. The stock has a market cap of $8.58 billion, a P/E ratio of -10.67 and a beta of 2.46. The company has a quick ratio of 9.12, a current ratio of 6.28 and a debt-to-equity ratio of 0.17. The business has a 50-day moving average of $74.13. Alnylam Pharmaceuticals has a twelve month low of $60.27 and a twelve month high of $124.21.
In other news, CEO John Maraganore sold 49,457 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $70.00, for a total transaction of $3,461,990.00. Following the completion of the transaction, the chief executive officer now owns 239,450 shares of the company’s stock, valued at approximately $16,761,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.60% of the stock is currently owned by insiders.
A number of hedge funds have recently modified their holdings of ALNY. Capital Investment Advisory Services LLC bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth $25,000. Meeder Asset Management Inc. grew its position in Alnylam Pharmaceuticals by 332.9% during the 1st quarter. Meeder Asset Management Inc. now owns 342 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 263 shares during the last quarter. Quadrant Capital Group LLC grew its position in Alnylam Pharmaceuticals by 543.2% during the 1st quarter. Quadrant Capital Group LLC now owns 521 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 440 shares during the last quarter. Price Wealth Management Inc. bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth $46,000. Finally, Flagship Harbor Advisors LLC bought a new stake in Alnylam Pharmaceuticals during the 1st quarter worth $47,000. Institutional investors and hedge funds own 89.71% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Recommended Story: Gross Domestic Product (GDP)
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.